pharmaphorum May 17, 2024
Johnson & Johnson has agreed a $850 million deal to acquire Proteologix that will give it a pair of early-stage bispecific antibodies with immunology applications, including a drug heading for phase 1 testing in atopic dermatitis (AD) and asthma.
The agreement, which also includes an unspecified milestone payment, is expected to close in the middle of this year subject to antitrust clearance and other customary closing conditions.
It bolsters J&J’s already evident expertise in bispecific drugs, which bundle two drug targets in a single medicine and have come to prominence in oncology. J&J’s current roster of bispecifics includes CD3xBCMA-directed Tecvayli (teclistamab) and CD3xGPRC5D Talvey (talquetamab), both used to treat blood cancers.
Proteologix’s lead candidate PX128 targets TSLP – currently drawing...
Today's Sponsors
Today's Sponsor